Hello all,
There was an interesting discussion on the thread recently on how it works when two drug companies are selling the same drug into the same market, but for different indications. How do they track sales for each indication? We were discussing this with respect to Targretin's cancer indications owned by LGND, and the metabolic / diabetes indications owned by LLY ... but this should be a frequently encountered issue with LGND's pipeline, their partnerships, and their strategy of reserving certain therapeutic areas for themselves, particularly cancer, while partnering other, more primary care areas.
Does anyone know about Amgen's deal with J&J on Epogen? If my memory serves me correct, J&J has the rights to market Epo into dialysis, and Amgen everywhere else. Also, if my memory serves me right, this has been a pretty acrimonious deal between the parties ... with significant litigation, I think over royalties.
Below I've posted a press release from today ... HMR announcing the availability of an anti-emetic ... they'll be selling it into chemotherapy patients, ABT will be selling the same product in the surgical setting.
Does anyone know anyone who has worked on one of these deals for a pharma company ... either negotiating it up front, or managing it once it's been established? It would be interesting to get their insight ...
Peter
Anzemet(R) Now Available in the United States For Oncology and Surgery Patients
KANSAS CITY, Mo., Feb. 24 /PRNewswire/ -- Hoechst Marion Roussel today announced that Anzemet(R) (dolasetron mesylate injection/tablets), an antiemetic that prevents the nausea and vomiting associated with chemotherapy and surgery, is now available in the United States. Anzemet is available in both intravenous and oral formulations.
A selective 5-HT3 receptor antagonist, Anzemet prevents the nausea and vomiting associated with single or repeated courses of emetogenic cancer chemotherapy (CINV). The intravenous formulation is also indicated for the prevention and treatment of postoperative nausea and vomiting (PONV); the oral formulation is indicated for the prevention of PONV.
If left untreated, an estimated 70 percent of cancer patients undergoing chemotherapy experience nausea or vomiting as a side effect of treatment. This potential is among the most distressing of cancer patients' treatment fears, causing some people to delay or abandon potentially curative treatment.
"In the past, some patients have chosen to forego cancer treatment because of their fear of side effects," said Gerald P. Belle, president, Hoechst Marion Roussel North America. "Preventing the nausea and vomiting associated with chemotherapy benefits patients and makes them more comfortable throughout the course of their therapy."
Nausea and vomiting also are issues in the surgical setting, where 20 to 30 percent of patients experience the conditions postoperatively, with higher frequency in gynecological, intra-abdominal and nose and middle ear procedures. Anzemet can be administered before surgery begins to prevent the condition, or the intravenous formulation can also be used to treat nausea and vomiting if they develop following surgery. The availability of Anzemet for postoperative use will be particularly welcome in treating patients who are at high risk for PONV and those for whom other antiemetics have been ineffective.
The potential for experiencing nausea and vomiting is shown in some studies of surgical patients to be a greater patient fear than postoperative pain. Troublesome PONV can prolong a patient's recovery room stay and is among the most common causes of hospital admission following outpatient surgery.
Hoechst Marion Roussel and Abbott Laboratories have entered into an agreement to market the injectable form and promote the oral form of Anzemet for PONV only. Under terms of the agreement, Abbott will be solely responsible for the promotion, sale and distribution of the Anzemet Injection 12.5-mg ampule for the prevention and treatment of PONV. Abbott also will be responsible for promotion of Anzemet Tablets for the prevention of PONV. Hoechst Marion Roussel will continue to promote Anzemet Injection and Tablets for the prevention of nausea and vomiting in chemotherapy patients.
The dosing convenience of Anzemet will be an important factor in its value to patients and health care professionals alike. The intravenous and oral formulations both offer single dosing vs a three- or four-dose regimen recommended for other antiemetics, and can be administered without dosage adjustment to a wide range of patients, including the elderly and those with renal or hepatic impairment.
Clinical Trials
Anzemet Injection and Tablets were evaluated in more than 70 clinical trials involving more than 10,000 patients worldwide. A wide range of patient populations was studied, including men, women, the elderly, and those with hepatic and renal impairment.
... |
